Fatty Liver Disease — MASLD

Understand it.
Reverse it.

One in three American adults has fatty liver disease. Most have no idea. Standard lab tests weren't designed to find it early — and that gap is costing lives.

1 in 3
American adults affected
85%
higher all-cause mortality vs. general population
~2×
increased cardiovascular event risk
📄Free Guide

What Your Doctor's
Tests Are Missing

A free consumer guide to fatty liver, hidden risk, and the evidence-backed path to reversal. Six sections. Peer-reviewed science. Yours free.

No spam. Unsubscribe anytime.

🔬 Evidence-based education
🩺 Certified practitioner network
🔒 No personal health data collected
📋 Peer-reviewed science
The Basics

Your liver does more than
you've been told

The liver is not just a detox organ. It sits at the center of your metabolic, cardiovascular, and hormonal health — and when it accumulates fat, the consequences reach far beyond the liver itself.

🫀

Cardiovascular Hub

The liver regulates lipid metabolism, insulin signaling, and inflammatory pathways that directly drive cardiovascular risk. A fatty liver is a stressed liver — and that stress reaches your heart.

⚖️

Metabolic Command Center

Glucose regulation, fat storage, and hormonal clearance all route through the liver. When overloaded with fat, these systems begin to misfire — often silently, for years.

🔕

The Silent Condition

Fatty liver rarely causes symptoms in its early stages. Most people have no idea. By the time symptoms appear, the reversal window may have passed.

85%

higher all-cause mortality in patients with fatty liver vs. the general population

Issa et al. · J Hepatol 2025 · n=13,099

~2×

increased cardiovascular event risk across 52 studies and diverse global populations

Zhong et al. · AJPC 2026 · 52-study meta-analysis

30–40%

of confirmed cases show completely normal liver enzymes — missed by standard screening

NASH Clinical Research Network

Risk accumulates across systems — before any single marker flags

Triglycerides+48 mg/dL avg
Insulin Resistance (HOMA-IR)+1.65 avg
GGT (liver enzyme)+13 U/L avg
LDL Cholesterol+8.5 mg/dL avg
hs-CRP (inflammation)+1.06 mg/L avg
HDL (protective cholesterol)−8.4 mg/dL avg

Average biomarker differences in patients with fatty liver vs. non-steatotic comparators. Each shift is subclinical individually — together they signal significant systemic strain. Source: Zhong et al., AJPC 2026.

The Detection Gap

Why it goes
undetected

Limitation 01

Liver enzymes weren't designed to screen for fatty liver

ALT and AST measure liver cell damage — not fat accumulation. Research shows that 30–40% of people with confirmed fatty liver have completely normal enzyme values. A normal result is not the same as a healthy liver.

Limitation 02

Imaging finds late-stage disease better than early

Elastography and ultrasound are designed to detect fibrosis and advanced structural change. Their sensitivity decreases significantly at early steatosis — precisely the stage where reversal is most achievable.

Limitation 03

Risk accumulates across systems, not in a single number

Fatty liver doesn't announce itself with one abnormal value. It builds silently through shifts in triglycerides, insulin resistance, inflammation markers, and liver function — each subclinical alone, but significant in combination.

7 Questions · 2 Minutes

What does your
risk pattern look like?

Our free assessment reviews factors most associated with fatty liver in the research literature. No personal health data is stored. No clinical conclusions are drawn — just a clearer picture of where you stand, and what to do next.

Start the Quiz

Takes about 2 minutes

The Good News

Fatty liver is one of the most
reversible metabolic conditions

When identified in the right window and addressed across root-cause systems, fatty liver can be meaningfully reversed. The key is a complete picture — not a partial one.

01

Identify the full pattern

Reversal begins with understanding which systems are under strain. Metabolic markers, inflammatory signals, insulin function, and liver-specific indicators together reveal what single tests cannot.

02

Address root causes, not symptoms

Dietary change, targeted movement, and metabolic support work at the system level. The liver responds rapidly to the right interventions when applied early enough.

03

Work with a practitioner who sees the whole picture

Practitioners trained in comprehensive cardiometabolic assessment are equipped to evaluate your full risk profile and design a reversal-oriented approach tailored to your biology.

04

Track progress with meaningful markers

Reversal is measurable. The same multi-system assessment that identifies risk can confirm improvement — giving you and your practitioner a clear signal that the intervention is working.

"It is important that we do not only focus on the liver when treating patients with fatty liver disease. A holistic approach and early intervention involving different medical specialities can be crucial to improve the prognosis."

— Issa G, Shang Y, Strandberg R, Hagström H, Wester A · Journal of Hepatology · 2025;83:643–651

Practitioner Directory

Find a practitioner trained to
see the full picture

Practitioners listed here have completed advanced cardiometabolic training through the CMiQCertified program. This directory does not represent the exclusive approach to fatty liver management.

Dr. Sarah Chen
DC, IFMCP · San Diego, CA
Core Liver-Metabolic Thyroid-Metabolic
🖥️ Telehealth & In-Person
Dr. Michael Torres
MD, ABOIM · Austin, TX
Core Liver-Metabolic
🏥 In-Person
Dr. Rachel Osei
NMD · Scottsdale, AZ
Core Liver-Metabolic Thyroid-Metabolic Perimenopausal-Thyroid-Metabolic
🖥️ Telehealth & In-Person